These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16792444)

  • 1. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.
    Spence MM; Hui R; Chan J
    J Manag Care Pharm; 2006 Jun; 12(5):377-82. PubMed ID: 16792444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
    Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
    Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
    J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
    Klepser DG; Huether JR; Handke LJ; Williams CE
    J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
    Cecil WT; Barnes J; Shea T; Coulter SL
    J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
    García Ruiz AJ; Leiva Fernández F; Martos Crespo F
    Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
    Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
    J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH; Dalal AA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():221-33. PubMed ID: 22500122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease].
    Schramm W; Haake D; Brandt A
    Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease.
    Nair KV; Wolfe P; Valuck RJ; McCollum MM; Ganther JM; Lewis SJ
    J Manag Care Spec Pharm; 2020 May; 26(5):575-585. PubMed ID: 32347176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
    Dalal AA; Shah M; D'Souza AO; Crater GD
    Respir Med; 2012 Jun; 106(6):829-37. PubMed ID: 22425138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
    Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
    Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
    Chatterjee A; Shah M; D'Souza AO; Bechtel B; Crater G; Dalal AA
    Respir Res; 2012 Feb; 13(1):15. PubMed ID: 22340019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
    Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.